Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Global health

Countries to explore pooled procurement of vaccines to reduce costs

Manica Balasegaram executive director of MSF

Source: Médecins Sans Frontières (MSF)

Manica Balasegaram, executive director of MSF’s Access Campaign

The World Health Assembly (WHA), the decision making body of the World Health Organization (WHO), has passed resolution that aims to improve the affordability and accessibility of vaccines — an important issue for low and middle income countries. 

The resolution calls for greater transparency around vaccine prices and for WHO member states to explore whether purchasing can be pooled between countries. 

During discussions, Latvia voiced concerns, on behalf of the European Union, that publishing vaccine prices may breach confidentiality agreements. Meanwhile Niger, which is currently facing a meningitis outbreak and is unable to afford the most effective vaccine according to Médecins Sans Frontières (MSF), reportedly made a plea for the resolution to be passed. 

MSF strongly supports the resolution and highlights that in the poorest countries the price of vaccinating a child is now 86 times more expensive than it was in 2001. “If governments do not take concrete action to address vaccine prices, they will be increasingly forced to make difficult choices about which diseases they can and can’t afford to protect their children against,” says Manica Balasegaram, executive director of MSF’s Access Campaign. 

In 2012, the WHA endorsed the Global Vaccine Action Plan, which was developed by a collaboration of immunisation experts and stakeholders, and aims to ensure that vaccination targets are met by 2020. However, progress has been slow.   

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068621

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.